Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 2
1(33.3%)
3Total
N/A(2)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT02959879Phase 2Completed

Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma

Role: collaborator

NCT07034703Not Yet Recruiting

Prospective Cohort of Patients Treated Using Neoadjuvant Modified FOLFIRINOX 6 Cycles for Potentially Resectable Pancreatic Duct Adenocarcinoma, Candidate for Participation in the PANACHE02 Clinical Trial

Role: collaborator

NCT01717924Not ApplicableRecruiting

Evaluation of Surgery Versus Primary Chemotherapy in Resectable Signet Ring Cell Gastric Adenocarcinoma

Role: collaborator

NCT04709055Not ApplicableUnknown

Complex Peri-operative Intervention in Older Patients With Cancer

Role: collaborator

NCT01927016Completed

Outcomes After Esophageal Cancer Surgery

Role: collaborator

All 5 trials loaded